Age-related macular degeneration (AMD) is a progressive, chronic retinal disorder predominantly affecting individuals over 55 years of age and represents the leading cause of central vision loss in developed countries [1]. With the global increase in the aging population, AMD is emerging as a significant socioeconomic and healthcare challenge [2]. The disease primarily targets the macula, the central portion of the retina responsible for high-resolution vision required for reading, facial recognition, and driving [3].

AMD is classified into two main types: dry (nonexudative) and wet (exudative). The dry form accounts for approximately 85–90% of cases and is characterized by drusen deposits, retinal pigment epithelium (RPE) atrophy, and progressive photoreceptor degeneration [4]. The wet form arises from choroidal neovascularization mediated by vascular endothelial growth factor (VEGF), resulting in fluid leakage, hemorrhage, and rapid central vision loss [5].

While less common, wet AMD is associated with the most severe vision loss among AMD patients. The pathophysiology of AMD is multifactorial, involving oxidative stress, chronic inflammation, genetic predisposition, and environmental risk factors such as smoking and poor dietary habits [6]. Oxidative damage to Bruch’s membrane and the retinal pigment epithelium (RPE) leads to the accumulation of waste products and impaired photoreceptor support, thereby promoting disease progression [7].

Genetic factors, including mutations in complement factor H and other components of the complement pathway, further increase individual susceptibility to AMD.

Therapeutic strategies for AMD have advanced considerably in recent decades. In wet AMD, intravitreal anti-VEGF therapy has revolutionized management, allowing stabilization or even improvement of vision in the majority of patients [8]. In contrast, dry AMD currently lacks definitive treatment; however, nutritional supplementation with antioxidants and zinc—as demonstrated in the Age-Related Eye Disease Study (AREDS)—has been shown to slow disease progression in intermediate-stage cases.

.      

New treatments, including complement inhibitors, stem cell treatment, and gene treatment, are on the horizon to treat unmet needs, particularly dry AMD [9]. Even with all of these advances, AMD continues to be a leading cause of disability, where it remains necessary to have earlier diagnosis, risk factor modification, and personalized treatment protocols [10]. For this article, the pathophysiology of AMD is studied and existing management protocols assessed in order to fully appreciate this severe ocular disease.      

This study was performed by systematically searching the literature published between 2010 and 2024 through databases like PubMed, Cochrane Library, and clinical trial registries. Randomized controlled trials (RCTs), meta-analyses, and observational studies in the area of AMD pathophysiology and management were included. Keywords for the search were "age-related macular degeneration," "pathophysiology," "anti-VEGF," "oxidative stress," and "management." Inclusion were studies that assessed disease mechanisms, genetic correlates, or treatment intervention with at least six months of follow-up. Wet and dry AMD were both included. Exclusion were case reports, pediatric macular degeneration studies, and non-peer-studied articles. Data extraction was on risk factors, pathophysiological mechanisms, efficacy of anti-VEGF drugs, and outcomes of nutritional and preventive trials. Aggregated results and tabulated qualitatively to contrast treatment effects and complications.

Evidence supports central mechanisms of oxidative stress, complement dysregulation, and genetic susceptibility in AMD. Anti-VEGF therapy was very effective in causing visual gain in wet AMD, whereas nutritional supplementation arrested progression in dry AMD but reversed no loss of vision.     Table 1: Pathophysiologic Factors in Age-Related Macular Degeneration (AMD)

Table 2: Management Strategies and Outcomes

the progression from intermediate to advanced disease. No treatment today, however, will regain lost vision [15]. The new developments with complement inhibitors, stem cell transplant, and neuro-protectants are promising but are still in the experimental phase. Public health interventions are also valuable. Early detection through conducting periodic ophthalmic screening, especially in the risk groups, can be beneficial for early intervention [16]. Patient education for the smoking behavior to be stopped, dietary modifications, and compliance 

This study underscores that age-related macular degeneration (AMD) is a complex, multifactorial disorder influenced by genetic, environmental, and cellular factors [11]. Oxidative stress and retinal pigment epithelium (RPE) dysfunction play central roles in disease progression, with strong evidence showing that smoking, poor diet, and genetic susceptibility accelerate risk [12]. The accumulation of drusen and subsequent complement system activation perpetuates retinal injury and inflammation, ultimately leading to irreversible photoreceptor loss. Therapeutic approaches differ substantially between dry and wet AMD. Anti-VEGF therapy has transformed the prognosis of wet AMD, converting a condition historically associated with irreversible blindness into a manageable disease [13]. Agents such as ranibizumab and aflibercept have demonstrated significant efficacy, maintaining or improving vision in up to 80% of patients. Nonetheless, challenges persist, including the need for frequent intravitreal injections, high treatment costs, and patient adherence, particularly in resource-limited settings [14]. Ongoing investigations into extended-release drug delivery systems and gene-based therapies aim to reduce these burdens and enhance patient compliance. Management of dry AMD remains limited. While AREDS-based nutritional supplementation may slow disease progression, it does not restore lost vision. These findings highlight the importance of personalized treatment approaches, where genetic testing—though not yet standard—could one day guide risk stratification and tailored interventions [17]. A multidisciplinary approach, involving ophthalmologists, genetic counselors, and rehabilitation specialists, can optimize functional outcomes and patient quality of life. Overall, although significant progress has been made in wet AMD treatment, therapeutic options for dry AMD continue to represent a substantial unmet clinical need [18]. Future research targeting molecular pathways, regenerative medicine, and preventive strategies will be essential in bridging this gap and reducing the global burden of AMD.

Age-related macular degeneration remains a leading cause of visual impairment, especially among older adults. Recognition of its multifactorial etiology has guided the development of effective treatments, particularly anti-VEGF therapy for wet AMD. For dry AMD, current interventions are limited to preventive measures and nutritional supplementation. Emerging therapies, including gene therapy, complement inhibitors, and regenerative medicine, hold promise for more comprehensive management in the future.

Early diagnosis, lifestyle modification, and individualized treatment strategies are critical for optimizing patient outcomes. Integrating these approaches with novel therapeutic developments represents the most effective strategy for preserving vision and improving quality of life in individuals affected by AMD.